Document Detail


Perceptions of practicing pharmacists in Idaho about a potential behind-the-counter drug program.
MedLine Citation:
PMID:  20587744     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In late 2007, the Food and Drug Administration (FDA) held public hearings exploring the establishment of a new behind-the-counter (BTC) drug program. However, little is known about the views of pharmacists regarding such a program.
OBJECTIVE: To assess the overall perceptions of Idaho's practicing pharmacists about the creation of a formal BTC drug program, the appropriateness of including certain drug categories, specific barriers to its adoption, and the impact of the new program on access to medicines.
METHODS: A survey of practicing pharmacists in Idaho was conducted by mail, utilizing anonymous responses. Key questions exploring the views of pharmacists about the new BTC drug program utilized 5-point Likert scales. Data were also collected on respondent characteristics.
RESULTS: A total of 357 practicing pharmacists in Idaho (31% response rate) returned the mail survey; 84% of pharmacists agreed that the FDA should be exploring an expanded BTC program, and 88% of pharmacists agreed that this program would improve access to some prescription-only products and convenience for patients. Almost 71% of pharmacists reported a personal willingness to both initiate and monitor certain BTC drug therapies. When focusing on specific drug categories for BTC status, the highest support was for selected agents within smoking cessation therapies (85%), nasal corticosteroids for allergies (81%), and vaccines (75%). Pharmacists who reported low barriers to the adoption of a new BTC program were significantly more likely to support this program than were those reporting high barriers. Only 39% of pharmacists agreed that adequate facilities were currently available for private evaluation and counseling of BTC patients.
CONCLUSIONS: Pharmacists in a statewide survey of perceptions regarding a new BTC drug program overwhelmingly believe that patients would benefit. Pharmacists strongly support the development of the new program, and more than two thirds indicate that they would likely participate, given the necessary supporting institutional framework. Perceived barriers are related to willingness to participate and likely can be minimized through education and provision of private consulting areas.
Authors:
Timothy L Hunt; Vaughn L Culbertson; John Erramouspe; Kerry Casperson
Related Documents :
10284204 - A comprehensive system for antimicrobial monitoring and review using a mandatory antimi...
2816954 - Pharmatrend as a management tool: capturing workload data.
10296064 - Enrollments in schools and colleges of pharmacy, 1988-1989.
18192134 - Pharmacy patronage: identifying key factors in the decision making process using the de...
10160554 - Assessment of need for a children's hospice program.
15625504 - African american community health advisors trained as research partners: recruitment an...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-06-29
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  44     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-26     Completed Date:  2010-12-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1403-9     Citation Subset:  IM    
Affiliation:
College of Pharmacy, Idaho State University, Pocatello, ID, USA. thunt@pharmacy.isu.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Attitude of Health Personnel*
Behind-the-Counter Drugs*
Community Pharmacy Services*
Data Collection
Health Knowledge, Attitudes, Practice
Health Services Accessibility / organization & administration*
Humans
Idaho
Patient Care*
Pharmacists / psychology*,  statistics & numerical data
Chemical
Reg. No./Substance:
0/Behind-the-Counter Drugs

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients.
Next Document:  Management of hypertension in renal transplant patients: a comprehensive review of nonpharmacologic ...